BioStack, a healthtech startup, has secured $9.5 million in seed funding to expand its clinical data network across the US, India, Brazil, and Argentina. Founded in 2025, the company consolidates fragmented hospital records to train medical AI models. In India, the startup is currently facilitating patient recruitment for an investigational cancer vaccine program, highlighting its role in clinical research.
BioStack, a San Francisco-based healthtech company, has raised $9.5 million in seed funding to expand its operations and technical infrastructure. The funding round was led by Peak XV, DCVC, and Afore Capital, with additional backing from Y Combinator. Founded in 2025 by Sanat Mishra and Parth Patwa, the firm aims to solve the problem of fragmented healthcare records by pulling together data from various hospitals into a single, unified format.
The company’s platform aggregates information such as clinical notes, laboratory results, medical imaging, and medication history. This data is converted into longitudinal datasets—comprehensive timelines of patient health—which are necessary for developing and training medical AI models. By creating these structured datasets, BioStack aims to help pharmaceutical researchers and AI developers build tools for precision medicine, where treatments are tailored to individual patient profiles.
In India, BioStack is already playing a role in clinical research by connecting patients to an investigational cancer vaccine program. While the pharmaceutical partner involved in this trial has not been disclosed, this initiative demonstrates how the company’s platform can be used to speed up the process of patient selection and drug discovery. The platform has already processed a vast amount of medical information, including hundreds of thousands of medical images and millions of transcripts from telehealth services.
Investment interest in the healthtech sector has seen a shift in 2026. While the number of total deals has declined, data suggests that capital deployment into the sector has risen by approximately 15% this year. This indicates that investors are increasingly favoring startups that have access to proprietary data and provide clear, practical tools for medical decision-making, rather than companies with broad, undefined goals.
For investors and industry observers, the primary factor to track will be BioStack’s ability to navigate the complex regulatory environment surrounding healthcare data. Handling sensitive patient information requires strict compliance with privacy laws in all operating regions, including India and the US. Any changes in data privacy regulations or issues regarding data security could pose a risk to the company’s expansion plans and operational model.
As BioStack continues to grow its engineering headcount and expand its data network, the company will need to demonstrate that its platform can effectively integrate with more healthcare providers to maintain the quality and scale of its records. The company's success will depend on its ability to maintain its data utility while adhering to global healthcare standards and expanding its footprint in the clinical research market.